Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Glaxosmithkline LLC

Other

Alan Peter Lewis

Paul Andrew Hamblin

Tejinder Kaur Bhinder

Jonathan Henry Ellis

Volker Germaschewski

Radha Shah Parmar

Martin Orecchia

Stephanie Jane Clegg

Susannah Karen Ford

Mark Uden

Trevor Anthony Kenneth Wattam

Claire Ashman

Laura Hook

Chika Akinseye

Qing Shan Zhang

Mark Brian Pepys

Zdenka Ludmila Jonak

Patrick A Mayes

Liuqing Yang

Jennifer L Craigen

John Robert White

Laurent S Jespers

Steven Grant

Paul Algate

Wenqing Jiang

Yangsheng Qiu

John Richard White

Michael Steward

Ian Richard Catchpole

Gerben Bouma

David Dixon

Stephanie Hopley

Jessica Lynn Neisen

Thomas Matthew Webb

Edward Thomas Coulstock

Rudolf M T De Wildt

Peter Ernest Soden

Gerald Wayne Gough

Herman Waldmann

Paul Alexander Wilson

Rudolf Maria De Wildt

Eric Dobrzynski

Valeriu Damian

Austin Keith Doyle

Laura Maria Halo

Emma R Harding

Xuan Hong

Chong Ding

Xu Feng

Yingli Ma

Yanjiao Zhou

Guhan Nagappan

Peter Morley

William John Kenneth Lewis

Gary Brian Finka

Michael Hoare

Ioannis Voulgaris

James S Crowe

Thomas Sandal

Zoe Hughes-Thomas

Claire Holland

Mary Birchler

Louise Walsh

Philippe Marc Louis Alard

Robyn Alexandra Emmins

Alexis Paul Godillot

Li Cui

Farhana Hussain

Alexis Pual Godillot

Adam Daniel McInally

Pamela Joan Thomas

Michael Neil Burden

Martin Anibal Orecchia

Radha Shah

Trevor Anthony Wattam

Thil Batuwangala

Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.

IL-7 binding proteins and their use in medical therapy

The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins

The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.

Biopharmaceutical compositions comprising antibody variants

The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.

Antibody variants

The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Antigen binding proteins

The present invention relates to a recombinant signal sequence derived from. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.

Method of producing a recombinant protein

The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Binding agonist for treatment of neurological and other disorders

The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.

Modified proteins and peptides

Biopharmaceutical compositions and related methods

This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Anti-LAG-3 binding proteins

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

Growing community of inventors

Stevenage, United Kingdom

Alan Peter Lewis